KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Gsk (GSK) Income towards Parent Company (2016 - 2026)

Gsk has reported Income towards Parent Company over the past 18 years, most recently at $2.3 billion for Q1 2026.

  • For Q1 2026, Income towards Parent Company rose 14.49% year-over-year to $2.3 billion; the TTM value through Mar 2026 reached $7.8 billion, up 24.3%, while the annual FY2025 figure was $7.6 billion, 130.05% up from the prior year.
  • Income towards Parent Company for Q1 2026 was $2.3 billion at Gsk, up from $846.0 million in the prior quarter.
  • Over five years, Income towards Parent Company peaked at $17.5 billion in Q4 2022 and troughed at -$75.4 million in Q3 2024.
  • A 5-year average of $3.5 billion and a median of $2.0 billion in 2023 define the central range for Income towards Parent Company.
  • Biggest five-year swings in Income towards Parent Company: plummeted 104.06% in 2024 and later skyrocketed 3704.42% in 2025.
  • Year by year, Income towards Parent Company stood at $17.5 billion in 2022, then crashed by 77.97% to $3.9 billion in 2023, then fell by 26.31% to $2.8 billion in 2024, then crashed by 70.3% to $846.0 million in 2025, then surged by 176.81% to $2.3 billion in 2026.
  • Business Quant data shows Income towards Parent Company for GSK at $2.3 billion in Q1 2026, $846.0 million in Q4 2025, and $2.7 billion in Q3 2025.